640 related articles for article (PubMed ID: 8732473)
1. Osteoporosis prevention clinical study program.
Delmas P; Gimona A
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
[TBL] [Abstract][Full Text] [Related]
2. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study.
Studd JW; MacCarthy K; Zamblera D; Dain MP
Scand J Rheumatol Suppl; 1996; 103():89-90. PubMed ID: 8966497
[TBL] [Abstract][Full Text] [Related]
4. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
5. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
Grey AB; Cundy TF; Reid IR
Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
[TBL] [Abstract][Full Text] [Related]
6. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.
Evans SF; Davie MW
Clin Endocrinol (Oxf); 1996 Jan; 44(1):79-84. PubMed ID: 8706298
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
8. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Cooper C; Stakkestad JA; Radowicki S; Hardy P; Pilate C; Dain MP; Delmas PD
Osteoporos Int; 1999; 9(4):358-66. PubMed ID: 10550454
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
[TBL] [Abstract][Full Text] [Related]
10. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
11. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
Insua A; Negri A; Zanchetta JR
Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
[TBL] [Abstract][Full Text] [Related]
12. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
13. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Alexandersen P; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042
[TBL] [Abstract][Full Text] [Related]
15. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
16. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
17. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
[TBL] [Abstract][Full Text] [Related]
18. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
Foster RH; Balfour JA
Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
20. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.
Stevenson JC; Teter P; Lees B
Maturitas; 2001 Apr; 38(2):197-203. PubMed ID: 11306209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]